Memory Pharmaceuticals News (NASDAQ:MEMY)
| Latest Memory Pharmaceuticals News Headlines | | Date | Time | Source | | | 08/26/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
- Results in Proceeds of $2.0 Million -
MONTVALE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007 equity financing agreement... More...>> |
| 08/13/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Reports Second Quarter 2008 Financial Results
MONTVALE, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today reported its financial results for the second quarter ended June 30, 2008.
"The clear highlight of the quarter was Roche's decision to license R3487/MEM 3454, which underscored the potential of our nicotinic alpha-7 program... More...>> |
| 08/06/2008 | 4:05PM | PRNUS | Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
MONTVALE, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced today that it will report its second quarter 2008 financial results on Wednesday, August 13, 2008 before the U.S. financial markets open. Management will provide a Company update and discuss the second quarter results... More...>> |
| 07/30/2008 | 4:28PM | PRNUS | Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008
MONTVALE, N.J., July 30 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago. The results demonstrate that MEM... More...>> |
| 06/24/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Closes Second Tranche of Equity Financing with The Stanley Medical Research Institute
- Results in Proceeds of $2 Million -
MONTVALE, N.J., June 24 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has secured $2 million through the sale of approximately 4.7 million shares of common stock under its equity financing agreement with an investment group led by The... More...>> |
| 06/09/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
- Company to Request a Hearing -
MONTVALE, N.J., June 9 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that on June 6, 2008 it received a letter from the NASDAQ Listing Qualifications Department notifying the Company that, because it has not regained compliance with the $1.00 bid... More...>> |
| 05/16/2008 | 12:00PM | PRNUS | Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's... More...>> |
| 05/14/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
MONTVALE, N.J., May 14 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today reported its financial results for the first quarter ended March 31, 2008.
"We had a productive start to 2008, reporting significant progress with our collaborations and refocusing our operations to advance four high-value... More...>> |
| 05/12/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals to Host R&D Day on May 16, 2008
MONTVALE, N.J., May 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY), today announced that it will host an R&D Day for the investment community on Friday, May 16, 2008 in New York City. Presentations will begin at 9:00 a.m. EDT and will focus on the Company's progress with its nicotinic alpha-7... More...>> |
| 05/07/2008 | 5:06PM | PRNUS | Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during... More...>> |
| 05/02/2008 | 6:05AM | PRNUS | Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
-Memory Receives $6 Million Milestone Payment-
MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) and Roche (SWX:ROG) today announced that Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' lead nicotinic alpha-7... More...>> |
| 04/04/2008 | 4:05PM | PRNUS | Memory Pharmaceuticals Receives Nasdaq Notification
MONTVALE, N.J., April 4, 2008 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that on April 2, 2008, it received notice from The Nasdaq Stock Market stating that the Company is no longer in compliance with the minimum $10.0 million stockholders' equity requirement for continued listing... More...>> |
| 03/28/2008 | 4:05PM | PRNUS | Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
MONTVALE, N.J., March 28 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today reported that the Company's independent registered public accounting firm included an explanatory paragraph in their opinion on the Company's financial statements included in the recently filed Annual Report on Form 10-K... More...>> |
| 03/12/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
-Expands PDE10 Collaboration with Amgen-
More...>> |
| 03/06/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
- Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 -
MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system... More...>> |
| 02/28/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced today that it will report its fourth quarter and full year 2007 financial results on Thursday, March 6, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the financial... More...>> |
| 02/19/2008 | 6:05AM | PRNUS | Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
- Establishes Plan for Biomarker Study -
MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and... More...>> |
| 02/07/2008 | 4:15PM | PRNUS | Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
MONTVALE, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that Vaughn M. Kailian has been appointed interim President & Chief Executive Officer. In support of Mr. Kailian's appointment, four of the Company's largest shareholders, MPM Capital, Great Point Partners, Oxford... More...>> |
| 02/05/2008 | 4:05PM | PRNUS | Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
MONTVALE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that James Sulat, President and Chief Executive Officer, will provide a company update at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 10:15 a.m. ET at The Waldorf=Astoria Hotel... More...>> |
| 12/20/2007 | 4:43PM | PRNUS | Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in cognitive impairment associated... More...>> |
|
|
|